Innogenetics N.V. (now Fujirebio Europe N.V.) was an internationalin vitro diagnostics (IVD) company, with headquarters inGhent, Belgium. Founded in 1985, the company developed and marketed IVD testing solutions as well as OEM raw materials. The company was acquired in September 2010 by JapaneseFujirebio Inc., an H.U. Group Holdings, Inc company, and changed name to Fujirebio Europe on October 1, 2013. The current CEO of Fujirebio Europe N.V. isChristiaan De Wilde.
Innogenetics was founded on 18 July 1985, byErik Tambuyzer,Hugo Van Heuverswyn andRudi Mariën. In 1992, the company launched the first commercial tests forcystic fibrosis inEurope (INNO-LiPA CFTR) and in 1993 the first commercial test forHepatitis C virus (HCV)genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test forhTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-Amyloid and in 2002 the first commercial test forHepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping).
The company was one of the first biotech companies to be listed on a Europeanstock exchange, in 1996 it was the first biotech company listed on EASDAQ, nowNASDAQ Europe. Until 2008 Innogenetics had its shares traded onEuronextBrussels.
Innogenetics N.V. was acquired byFujirebio in 2010 and changed name to Fujirebio Europe N.V. on October 1, 2013.
